Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 ...

Investment analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Get Free Report) in a report released on Monday. The firm set a “hold” rating on the stock. Other equities ...

TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

Equities research analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Get Free Report) in a report issued on Sunday. The brokerage set a “hold” rating on the stock.

After holding leadership positions at contract manufacturers Patheon and Thermo Fisher Scientific, working in the food and ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

Successful men gravitate toward athleisure brands like Alo and Lululemon for comfortable work pants. Buck Mason is also ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?